The Central Drugs Standard Control Organisation (CDSCO) has recently flagged over 50 drugs as “not of standard quality” (NSQ). This alarming revelation has significant implications for public health and safety. Here are the key points you need to know:
- Scope of the Issue: The CDSCO identified over 50 drugs, including widely used medications like Paracetamol and Pantoprazole, as sub-standard.
- Types of Medications Affected: The list includes a variety of drugs such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines.
- Specific Drugs Highlighted: Notable mentions include Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd, and calcium and vitamin D3 tablets from Pure & Cure Healthcare Pvt. Ltd.
- Geographical Spread: The sub-standard drugs were produced in various regions, including Himachal Pradesh, Hyderabad, Waghodia, Vadodara, Andhra Pradesh, and Indore.
- Pharmaceutical Companies Involved: Companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), and Meg Lifesciences were among those flagged.
- Industry Response: Some pharmaceutical companies have denied responsibility, claiming that the flagged drugs are spurious and not manufactured by them.
- Regulatory Actions: The CDSCO conducts monthly random sampling to ensure drug quality, and this report is part of their ongoing efforts to maintain high standards.
- Public Health Concerns: The failure of commonly used drugs like Paracetamol to meet quality standards raises significant public health concerns, especially for medications used for pain and fever relief.
- Historical Context: This is not the first time the CDSCO has flagged sub-standard drugs. Previous reports have also highlighted similar issues, indicating a persistent problem in the pharmaceutical industry.
- Consumer Awareness: It is crucial for consumers to stay informed about the quality of medications they use and to report any adverse effects to healthcare providers immediately.
-
Crypto ETFs Are Going Mainstream — But the Volatility Is a Trap Most New Investors Are Walking Right Into
Every major financial shift in history has had two groups of people: those who understood the rules of
-
The AI ETF Boom: How Artificial Intelligence Is Picking Stocks Better Than Fund Managers
For decades, the investment world ran on a simple hierarchy: the smartest humans with the best data and
-
How a ₹500 Per Month SIP in an ETF Can Beat Your Fixed Deposit in 10 Years — The Math Will Shock You
Most Indians still think of a Fixed Deposit as the gold standard of saving. It feels safe, it
-
India’s ETF Market Just Broke All Records — The One Precious Metal Driving the Frenzy
India’s exchange-traded fund market has just had its most explosive year on record, and at the center of
-
Gold ETFs Are Hitting Record Highs in 2026 — Here’s the Surprising Reason It Has Nothing to Do With Fear
Every time gold makes headlines, the story gets told the same way. Markets panic, investors flee to safety,
-
Why Active ETFs Are Quietly Replacing Mutual Funds — And Most Investors Haven’t Noticed Yet
The investment world is experiencing one of its most significant structural shifts in decades, and the majority of
